Meyer-Michel Samama
Overview
Explore the profile of Meyer-Michel Samama including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
685
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mullier F, Douxfils J, Tamigniau A, Dogne J, Horellou M, Flaujac C, et al.
Ann Biol Clin (Paris)
. 2015 Apr;
73(3):333-44.
PMID: 25857818
Non-VKA oral anticoagulants (NOACs), thanks to their ease of use and their similar or superior safety/efficacy profiles versus warfarin, have now widely reached the lucrative market of anticoagulation. However, while...
2.
Yusen R, Hull R, Schellong S, Tapson V, Monreal M, Samama M, et al.
Thromb Haemost
. 2013 Oct;
110(6):1152-63.
PMID: 24085227
The EXCLAIM study enrolled hospitalised acutely ill medical patients with age >40 years and recently-reduced mobility into a trial of extended-duration anticoagulant thromboprophylaxis. This post-hocanalysis evaluated the impact of age...
3.
Samama M, Amiral J, Guinet C, Le Flem L, Seghatchian J
Expert Rev Hematol
. 2013 Apr;
6(2):155-64.
PMID: 23547865
New oral anticoagulants are directed towards a single target, essentially factor Xa (FXa) or factor IIa. They do not require routine coagulation monitoring. However, in special clinical settings (emergency surgery,...
4.
Turpie A, Hull R, Schellong S, Tapson V, Monreal M, Samama M, et al.
Stroke
. 2012 Nov;
44(1):249-51.
PMID: 23117723
Background And Purpose: The optimal duration of venous thromboembolism prophylaxis in acute stroke patients is unknown. This subanalysis of the Extended Prophylaxis for Venous ThromboEmbolism in Acutely Ill Medical Patients...
5.
Lillo-Le Louet A, Wolf M, Soufir L, Galbois A, Dumenil A, Offenstadt G, et al.
Thromb Haemost
. 2012 Jul;
108(3):583-5.
PMID: 22782645
No abstract available.
6.
Hull R, Schellong S, Tapson V, Monreal M, Samama M, Nicol P, et al.
Ann Intern Med
. 2010 Jul;
153(1):8-18.
PMID: 20621900
Background: Extended-duration low-molecular-weight heparin has been shown to prevent venous thromboembolism (VTE) in high-risk surgical patients. Objective: To evaluate the efficacy and safety of extended-duration enoxaparin thromboprophylaxis in acutely ill...
7.
Gerotziafas G, Papageorgiou C, Hatmi M, Samama M, Elalamy I
Pathophysiol Haemost Thromb
. 2009 Jan;
36(3-4):204-11.
PMID: 19176993
Cancer is linked with hypercoagulability and risk of thrombosis and this close association was recognized by Armand Trousseau in 1865. The relation between cancer and blood coagulation is reciprocal: cancer...
8.
Cohen A, Agnelli G, Anderson F, Arcelus J, Bergqvist D, Brecht J, et al.
Thromb Haemost
. 2007 Oct;
98(4):756-64.
PMID: 17938798
Venous thromboembolism (VTE) is often asymptomatic, mis-diagnosed, and unrecognized at death, and there is a lack of routine postmortem examinations. These factors are thought to result in marked underestimates ofVTE...
9.
Hull R, Schellong S, Tapson V, Monreal M, Samama M, Turpie A, et al.
J Thromb Thrombolysis
. 2006 Jun;
22(1):31-8.
PMID: 16786230
Background: Venous thromboembolism (VTE) is a significant cause of mortality and morbidity in medical patients. Although thromboprophylaxis with enoxaparin reduces the risk of VTE in these patients, the optimal duration...
10.
Samama M, Dahl O, Mismetti P, Quinlan D, Rosencher N, Cornelis M, et al.
Haematologica
. 2006 Jan;
91(1):64-70.
PMID: 16434372
Background And Objectives: Venous thromboembolism (VTE) is a complex disorder influenced by numerous risk factors, and occurs frequently in at-risk hospitalized patients. Because appropriate prevention with thromboprophylaxis is underused, we...